四药联合治疗新诊断多发性骨髓瘤微小残留病的分子预测因子
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
多组学分析发现新诊断多发性骨髓瘤患者基线基因组、转录组和表观遗传特征与四药联合诱导治疗后MRD状态相关。研究纳入接受isatuximab、carfilzomib、lenalidomide和dexamethasone诱导治疗及MRD指导巩固治疗的患者样本。
多组学分析显示新诊断多发性骨髓瘤患者基线基因组、转录组和表观遗传特征与诱导治疗后MRD状态相关。
Nature Medicine, Published online: 19 October 2026; doi:10.1038/s41591-026-04692-0
In a multiomic analysis of samples from patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide and dexamethasone induction therapy followed by consolidation treatment guided by minimal residual disease (MRD) status, baseline genomic, transcriptomic and epigenetic features are associated with MRD status after induction.
来源:Nature Medicine · nature.com